[
  {
    "ts": null,
    "headline": "4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer",
    "summary": "These great dividend stocks merit more attention from income investors.",
    "url": "https://finnhub.io/api/news?id=e33946bc6cbbbefa6071fd3f69fc3ec3dfe847b9f871390759dff89f6b6e07e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760293680,
      "headline": "4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer",
      "id": 137060122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These great dividend stocks merit more attention from income investors.",
      "url": "https://finnhub.io/api/news?id=e33946bc6cbbbefa6071fd3f69fc3ec3dfe847b9f871390759dff89f6b6e07e4"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer (NYSE:PFE) Using Too Much Debt?",
    "summary": "Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...",
    "url": "https://finnhub.io/api/news?id=5dd1bf4285a4a2b796b9977454b8a9f8611243fb83514fec8a52b3f71c7d8faf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760270410,
      "headline": "Is Pfizer (NYSE:PFE) Using Too Much Debt?",
      "id": 137063679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...",
      "url": "https://finnhub.io/api/news?id=5dd1bf4285a4a2b796b9977454b8a9f8611243fb83514fec8a52b3f71c7d8faf"
    }
  },
  {
    "ts": null,
    "headline": "Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs",
    "summary": "Discover top S&P 500 dividend stocks with high yields and strong free cash flow. See analyst forecasts and find income opportunities.",
    "url": "https://finnhub.io/api/news?id=d46968558311326462f4178680901a08ea6f03bb0a277990f7aaa722331a0a55",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760263895,
      "headline": "Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs",
      "id": 137058163,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223715508/image_2223715508.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover top S&P 500 dividend stocks with high yields and strong free cash flow. See analyst forecasts and find income opportunities.",
      "url": "https://finnhub.io/api/news?id=d46968558311326462f4178680901a08ea6f03bb0a277990f7aaa722331a0a55"
    }
  },
  {
    "ts": null,
    "headline": "Will Zymeworks’ (ZYME) New R&D Leadership Mark a Turning Point in Its Oncology Strategy?",
    "summary": "Zymeworks Inc. recently appointed Adam Schayowitz, Ph.D., MBA, as Acting Chief Development Officer to accelerate its pipeline and partnership integration, leveraging his nearly 20 years of oncology drug development experience. Dr. Schayowitz’s background in leading global development programs at Pfizer and Tesaro positions Zymeworks to potentially strengthen both its R&D execution and collaborative ventures in the oncology space. We'll examine how Dr. Schayowitz's leadership experience could...",
    "url": "https://finnhub.io/api/news?id=ee5917ba68769760214637993ba80b18b0fe5be6610bc69a3b0cdebe2cc11fcb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760245977,
      "headline": "Will Zymeworks’ (ZYME) New R&D Leadership Mark a Turning Point in Its Oncology Strategy?",
      "id": 137063680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Zymeworks Inc. recently appointed Adam Schayowitz, Ph.D., MBA, as Acting Chief Development Officer to accelerate its pipeline and partnership integration, leveraging his nearly 20 years of oncology drug development experience. Dr. Schayowitz’s background in leading global development programs at Pfizer and Tesaro positions Zymeworks to potentially strengthen both its R&D execution and collaborative ventures in the oncology space. We'll examine how Dr. Schayowitz's leadership experience could...",
      "url": "https://finnhub.io/api/news?id=ee5917ba68769760214637993ba80b18b0fe5be6610bc69a3b0cdebe2cc11fcb"
    }
  }
]